117 lines
7.4 KiB
HTML
117 lines
7.4 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="en">
|
||
<head>
|
||
<meta charset="utf-8">
|
||
<base target="_blank">
|
||
<style>
|
||
body{font-family:system-ui,sans-serif;max-width:50rem;margin:2rem auto;line-height:1.6;padding:1rem}
|
||
img,iframe{max-width:100%}
|
||
.post-content{background:#f9f9f9;padding:1rem;border-radius:5px;margin:1rem 0}
|
||
.archive-header{background:#f0f8ff;border:1px solid #e0e0e0;border-radius:5px;padding:0.75rem;margin-bottom:1rem;font-size:0.9rem}
|
||
.archive-info{margin-bottom:0.5rem;color:#666}
|
||
.archive-source{color:#666}
|
||
.archive-header a{color:#007acc;text-decoration:none}
|
||
.archive-header a:hover{text-decoration:underline}
|
||
@media (prefers-color-scheme: dark) {
|
||
.archive-header{background:#1a1a2e;border-color:#333;color:#e0e0e0}
|
||
.archive-info, .archive-source{color:#ccc}
|
||
.archive-header a{color:#66b3ff}
|
||
}
|
||
</style>
|
||
</head>
|
||
<body>
|
||
|
||
<div class="archive-header">
|
||
<div class="archive-info">
|
||
<strong>📄 Archived:</strong> 2025-08
|
||
</div>
|
||
<div class="archive-source">
|
||
<strong>🔗 Source:</strong> ChatGPT o3
|
||
</div>
|
||
</div>
|
||
|
||
<h1>Methods for feminization with minimal fertility loss</h1>
|
||
|
||
<div class='post-content'>
|
||
|
||
<div class="md">
|
||
|
||
<h3>Methyl-estradiol-propanoate ( MEP )</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Boosts facial collagen, elastin and hydration in ≈12 weeks; no evidence it shifts deep sub-Q fat.</li>
|
||
<li><strong>Hair:</strong> Neutral.</li>
|
||
<li><strong>Fertility:</strong> Blood E2, LH and FSH stayed unchanged for 20 weeks in Emepelle trials. (<a href="https://pubmed.ncbi.nlm.nih.gov/31860210/?utm_source=chatgpt.com" title="Evaluation of Efficacy of a Skin Care Regimen Containing Methyl ...">PubMed</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>17-α-Estradiol 0.025 % lotion</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Slight sebum reduction; no body-fat redistribution.</li>
|
||
<li><strong>Hair:</strong> ↑ hair count & shaft diameter after 4-8 months.</li>
|
||
<li><strong>Fertility:</strong> Serum E2 ≤ 30 pmol L⁻¹; T & LH unchanged over 8 months. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3412238/?utm_source=chatgpt.com" title="The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® ...">PMC</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Equol / Genistein 0.5–1 % cream</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Modest ER-β activation improves texture; fat unchanged.</li>
|
||
<li><strong>Hair:</strong> In-vitro DHT scavenging; early human data only.</li>
|
||
<li><strong>Fertility:</strong> Endocrine-silent at topical doses so far.</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Clascoterone 7.5 % solution (<em>Breezula</em>)</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Cuts sebaceous activity; useful for hormonal acne.</li>
|
||
<li><strong>Hair:</strong> \~15 hairs cm² gain at 6 mo in Phase II male AGA trials.</li>
|
||
<li><strong>Fertility:</strong> Plasma drug < 5 ng mL⁻¹; no DHT, T or LH change detected. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10173235/?utm_source=chatgpt.com" title="Androgenetic Alopecia: Therapy Update - PMC">PMC</a>, <a href="https://www.jaad.org/article/S0190-9622%2819%2931086-2/fulltext?utm_source=chatgpt.com" title="A summary of in vitro, phase I, and phase II studies ...">jaad.org</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Topical Finasteride 0.25 % spray</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Minor sebum drop.</li>
|
||
<li><strong>Hair:</strong> Density gains comparable to oral; serum DHT ↓ 25–30 %.</li>
|
||
<li><strong>Fertility:</strong> T and semen normal over 24 wks; long-term data pending. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/?utm_source=chatgpt.com" title="Efficacy and safety of topical finasteride spray solution for male ...">PMC</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/34634163/?utm_source=chatgpt.com" title="Efficacy and safety of topical finasteride spray solution for male ...">PubMed</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Spironolactone 5 % lotion</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Potent oil control.</li>
|
||
<li><strong>Hair:</strong> Small studies show thicker hair with twice-daily use.</li>
|
||
<li><strong>Fertility:</strong> Plasma drug sub-ng; no measurable sex-hormone shift to date. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10010138/?utm_source=chatgpt.com" title="The Efficacy and Safety of Oral and Topical Spironolactone in ...">PMC</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/36039391/?utm_source=chatgpt.com" title="Dermoscopic evaluation of the efficacy of combination of topical ...">PubMed</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>GHK-Cu peptide 0.05–0.1 % serum</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Collagen & elastin up-regulation; no fat effect.</li>
|
||
<li><strong>Hair:</strong> Thickens shafts, signals follicle repair.</li>
|
||
<li><strong>Fertility:</strong> Hormone-neutral. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/?utm_source=chatgpt.com" title="Regenerative and Protective Actions of the GHK-Cu ...">PMC</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Hyaluronic-acid cheek fillers</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Instantly add mid-face volume, mimicking feminine fat pads; MRI shows persistence 2–15 yrs.</li>
|
||
<li><strong>Hair:</strong> None.</li>
|
||
<li><strong>Fertility:</strong> None. (<a href="https://pubmed.ncbi.nlm.nih.gov/39015357/?utm_source=chatgpt.com" title="Hyaluronic Acid Filler Longevity in the Mid-face: A Review ...">PubMed</a>, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9007185/?utm_source=chatgpt.com" title="Long-term MRI Follow-up of Hyaluronic Acid Dermal Filler">PMC</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Autologous facial fat grafting</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Permanent or long-lasting cheek & jaw softening with your own tissue.</li>
|
||
<li><strong>Hair:</strong> None.</li>
|
||
<li><strong>Fertility:</strong> None. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11249923/?utm_source=chatgpt.com" title="Improving the Retention of Low-Volume Autologous Fat ...">PMC</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<h3>Systemic estradiol patch / tablet (25–100 µg day⁻¹)</h3>
|
||
<ul>
|
||
<li><strong>Skin / fat:</strong> Only proven non-surgical route to true gluteo-femoral (“hour-glass”) fat shift.</li>
|
||
<li><strong>Hair:</strong> Lowers scalp androgen load, supporting growth.</li>
|
||
<li><strong>Fertility:</strong> Predictable LH/FSH suppression and spermatogenesis risk—bank sperm or use hCG co-therapy if chosen. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6795075/?utm_source=chatgpt.com" title="Determinants of body fat distribution in humans may ...">PMC</a>)</li>
|
||
</ul>
|
||
<hr />
|
||
<p><strong>Key take-away:</strong>
|
||
Topical soft-estrogens, peptide serums and modern anti-androgen lotions can soften skin and guard hair with minimal testosterone loss—but <strong>distinctly feminine body-fat curves still require either systemic estradiol or physical volume (fillers / fat grafts), both of which spare male fertility far better than full-dose systemic estrogen.</strong></p>
|
||
|
||
</div>
|
||
</div>
|
||
|
||
</body>
|
||
</html>
|